New drug strategy aims to stop aggressive head & neck cancer from coming back
NCT ID NCT02769520
Summary
This study is testing if a drug called pembrolizumab can help people with recurrent head and neck cancer stay cancer-free for longer after a second surgery. The drug is an immunotherapy designed to help the body's own immune system fight the cancer. Researchers will give the drug to about 45 patients after surgery and track how long they remain disease-free.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
-
University of California Los Angeles
Torrance, California, 90505, United States
-
University of California San Francisco
San Francisco, California, 94115, United States
Conditions
Explore the condition pages connected to this study.